If you want to distinguish your goods, services or both from those of another company, you may need a trademark or trade name. Find out what they are, what their registration procedure is and what it involves.
Information on the deadlines for filing applications for transformation of European Union trademarks into Spanish national trademarks. See more
If you have a new device, product or procedure that solves a technical problem or has a practical advantage, there are different ways to protect it in Spain and other countries. Find out how.
Does your innovation lie in the aesthetics, ornamentation or appearance of your product? Protect it through industrial design. Find out what rights registration confers and how to proceed.
Geographical indications protect the name of a product that has a specific geographical origin and owes its qualities, characteristics or reputation to its particular origin. Find out what they are, how the registration process works and what benefits they provide.
Patents published worldwide are a valuable source of scientific, technical and commercial information.
El Bono 3 del Fondo para PYMEs 2025, que cubre la elaboración de Informes Tecnológicos de Patentes (ITP) y Búsquedas Retrospectivas se cerrará el lunes 10 de febrero de 2025 al cierre de la jornada laboral. Próximamente se informará sobre su reapertura. Puede consultar más información aquí.
If you are an entrepreneur or a company and you want to boost and improve the profitability of your business by adequately protecting the intangible assets of your organisation, in this space you will find what you need.
138
results.
Updated on
15/07/2026 [08:22:00]
Results 75 to 100 of 138
Absstract of: WO2025038406A1
A series of non-peptide mu opioid receptor (MOR) selective modulators is provided. The compounds have the general formula (I) where R is (II) and where one of a, b, c, d, e or f is the point of attachment of indole ring R to the epoxymorphinan skeleton; at least one of the atoms at positions a, b, c, d, e and f is N; the remaining atoms at positions at a, b, c, d, e and f are CH; and * is a chiral carbon. The compounds are generally MOR antagonists and are used to treat disorders related to opioid receptor functions such as opioid addiction and opioid overdose, for the treatment of neurological diseases and for the treatment of pain, without causing constipation.
Absstract of: WO2026122407A1
Abeta binders are provided, as well as related polynucleotides, vectors, host cells, methods of production, compositions (e.g., pharmaceutical compositions), uses, and methods of use, e.g., for treatment of Alzheimer's disease.
Absstract of: WO2026118958A1
The present application relates to an hM4Di mutant and the use thereof in the preparation of a drug for treating Parkinson's disease. Compared with wild-type hM4Di, the hM4Di mutant comprises one or more of amino acid mutations Y439A, Y439G, W435A or W435G. The use comprises the use of an AAV expression vector containing a polynucleotide encoding the hM4Di mutant and an hSyn promoter, in combination with clozapine-N-oxide, in the preparation of a drug for treating Parkinson's disease.
Absstract of: US20260158046A1
Provided herein are methods of treating a neurodegenerative disorder (e.g., Parkinson's Disease) or a symptom thereof in a patient, by administering to the patient doxycycline (or a pharmaceutically acceptable salt thereof) either alone or in combination with other therapeutic agents (e.g., levodopa).
Absstract of: US20260158002A1
An application of a composition in improving or treating cognitive impairment. The composition contains 3-methyl-1-phenyl-2-pyrazolin-5-one or a pharmaceutically acceptable salt thereof and borneol or dexborneol. The cognitive impairment comprises Alzheimer's disease (AD), vascular dementia (VD), mild cognitive impairment (MCI), and other types of dementia.
Absstract of: WO2026122681A1
Aspects of the present disclosure relate, at least in part, to the creation of a human induced pluripotent stem cell line that can be induced to various brain cell types to be used for high throughput drug screens for agents that reduce lipid burden and AD related pathological features. The disclosure also provides details on several compounds that are useful for treating neurodegenerative diseases such as Alzheimer's disease.
Absstract of: WO2026117926A1
Provided is new use of the compound represented by formula (I). The compound represented by formula (I) has excellent anti-inflammatory activity, can effectively inhibit the activity of galectin-3, reduce neuroinflammatory responses, improve cognitive function, reduce the overactivation of microglia, reduce the deposition of Aβ, and palliate synaptic degeneration, and is used for treating Alzheimer's disease.
Absstract of: WO2026118416A1
Provided are an antibody that targets a P-Tau181 protein, or an antigen-binding fragment thereof and the use thereof. The provided antibody can specifically recognize and bind to the P-Tau181 protein, and does not recognize p-Tau217 and non-phosphorylated Tau proteins, and therefore can be used for preparing detection formulations or kits for diagnosing p-Tau181 protein-related diseases, such as Alzheimer's disease.
Absstract of: US20260158142A1
Provided are engineered cells that include a T cell receptor (TCR) or antigen-binding fragment thereof that binds to amyloid beta, and methods of engineering and using such cells, such as in methods of treatment, diagnosis, and monitoring of therapeutic effectiveness, of diseases or conditions, such as those associated with amyloid beta, e.g., Alzheimer's Disease.
Absstract of: US20260159559A1
0000 A method of treating Alzheimer's Disease (AD) is disclosed. The method comprises administering to the subject a therapeutically effective amount of an agent which prevents the binding of amyloid precursor protein (APP) to Tau protein.
Absstract of: WO2026122090A1
Embodiments of the invention include a system and method of using biomarkers in the diagnosis of Alzheimer's disease. A subject can be screened for Alzheimer's disease based on altered expression of one or more biomarkers in blood, plasma or saliva from the subject. Embodiments include 43 specific mRNA biomarkers to screen or distinguish healthy individuals from individuals affected with Alzheimer's disease. The biomarkers can also be used to determine the prognosis of a subject with the disease and identify early-onset and/or asymptomatic Alzheimer's disease.
Absstract of: WO2026119142A1
The present invention belongs to the technical field of medicine. Specifically disclosed are a compound represented by formula I, and a use thereof. The compound of the present invention has a structure represented by formula I, the definitions of each group and substituent being as described in the description. The compound of the present invention can be used for the treatment or prevention of neurodegenerative diseases such as Alzheimer's disease, Parkinson's disease, progressive multiple sclerosis, amyotrophic lateral sclerosis, dry age-related macular degeneration, and the like.
Absstract of: WO2025031917A1
The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Absstract of: US2025059165A1
0000 The present disclosure provides certain piperidinylpyridinylcarbonitrile derivatives, and pharmaceutically acceptable salts thereof, that are inhibitors of Glutaminyl-peptide cyclotransferase (QPCT) and glutaminyl-peptide cyclotransferase-like protein (QPCTL), and are therefore useful for the treatment of diseases treatable by inhibition of QPCT/L. Also provided are pharmaceutical compositions containing the same, and processes for preparing said compounds.
Absstract of: EP4755391A1
0001 Neurological disorders, Parkinson's disease and Multiple System Atrophy (MSA) cause serious socio-economic problems as there are, at present only therapies that treat the symptoms. Parkinson's research is a highly competitive field focusing on the specific drug targeting of the aggregation of alpha-synuclein (SYN). The discovery of Tubulin Polymerization Promoting Protein (TPPP) was a crucial factor in anti-Parkinson research. TPPP is a prominent pathological partner of SYN, which shifts the SYN-SYN aggregation toward the formation of fatal SYN-TPPP assemblies. The disassembly of the SYN-TPPP by specific agents may eliminate the toxicity of the pathological assembly of SYN by the proteolytic degradation of the excess SYN and leads to the recovery of the physiologically active proteins.
Absstract of: US20260151348A1
0000 The invention relates to engineered umbilical cord mesenchymal stem cell exosomes (hUCMSC-EVs) loaded with siCCR5, their preparation method, and their use in treating Alzheimer's disease. A lipid membrane is first prepared and dissolved, followed by incorporation of siCCR5 and hUCMSC-EVs. Using a cationic liposome extrusion technique, siCCR5 is efficiently delivered into the exosomes to obtain siCCR5-loaded engineered EVs. The resulting exosomes promote tissue regeneration, repair brain tissue, and modulate the brain microenvironment without causing toxicity. By carrying siCCR5, which targets a specific gene, the engineered EVs exhibit stronger targeted therapeutic effects and enhanced anti-inflammatory activity compared to conventional hUCMSC-EVs, thereby improving Alzheimer's disease progression.
Absstract of: AU2025321641A1
The present invention provides a use of lactoferrin in combination with ergothioneine in the preparation of a drug for preventing and/or treating Alzheimer's disease. Compared with the use of lactoferrin or ergothioneine alone, in the present invention, the combined use of lactoferrin and ergothioneine at a specific ratio as an active pharmaceutical ingredient can reduce cell damage caused by Aβ25-35, reduce the expression of a p-Tau protein, lower the oxidative stress level and regulate apoptosis, alleviate memory impairment and cognitive dysfunction, and can reduce Aβ deposition in mouse plasma.
Absstract of: US20260151441A1
The present invention relates to a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease, comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The present invention provides a composition for preventing, alleviating or treating cognitive impairment or Alzheimer's disease (AD), comprising a Lactobacillus delbrueckii subsp. lactis strain as an active ingredient. The strain of the present invention has the excellent effects of reducing amyloid beta protein (Aβ) or tau protein (Tau) and improving cognitive function, and thus can be effectively used as a composition for preventing, alleviating or treating cognitive impairment or AD.
Absstract of: WO2026112688A1
Disclosed herein are methods for treating a motor neuron disease such as amyotrophic lateral sclerosis (ALS) comprising administering mEphA4-Fc with an interval of greater than every week, for example administering mEphA4-Fc every two weeks, every three weeks, or every four weeks, and at a concentration of about 10 to about 40 mg/kg body weight of a subject.
Absstract of: WO2026112697A1
The present disclosure relates to a method of treating or ameliorating symptoms of a motor neurone disease and improving motor neuron survival in a subject, more specifically treating or ameliorating symptoms of amyotrophic lateral sclerosis (ALS) and related neurodegenerative disorders. The treatment method comprises administering a Janus kinase (JAK) inhibitor in combination with one or more compounds selected from a glutamate antagonist and an N-methyl-D-aspartate (NMDA) receptor antagonist, in particular baricitinib in combination with riluzole and/or memantine, and compositions and kits thereof for same.
Absstract of: WO2026117675A1
Methods for treating and preventing Parkinson's disease have been developed wherein allopregnanolone is administered to a human in need thereof in an amount between about 2 mg and about 6 mg, preferably 4 mg per dose. The methods include administering a dosage of from 2 mg to 6 mg, preferably 4 mg, to the subject once within a 24 hour period. The dosing is repeated every seven days, or less frequently.
Absstract of: WO2026114612A1
The present invention relates to compounds of formula (I) as TMEM175 modulators for reducing alpha-synuclein aggregation for the treatment of Parkinson's disease.
Absstract of: US20260151386A1
0000 This disclosure relates to dosage forms comprising bupropion hydrochloride, another salt form of bupropion, or the free base form of bupropion; dextromethorphan hydrobromide, another salt form of dextromethorphan, or the free base form of dextromethorphan, and a polymer. In some embodiments, the dosage form has no significant dose dumping of bupropion in the presence of ethanol in vitro. In some embodiments, the dosage form does not have a food effect for bupropion or dextromethorphan when taken with a high-fat meal in human subjects. Some embodiments include a method of treating a nervous system condition (such as depression, e.g., major depressive disorder, including treatment-resistant depression, agitation associated with Alzheimer's disease (or agitation associated with dementia of the Alzheimer's type), agitation associated with dementia, anxiety (or generalized anxiety disorder), neuropathic pain, or peripheral diabetic neuropathic pain) comprising, administering a dosage form described herein to a human being in need thereof.
Absstract of: KR20260081510A
본 발명은 식혜를 유효 성분으로 포함하는 파킨슨 질환을 예방 또는 치료하며 유산균, 레보도파. 도파민 수용제 자극제 및 도파민 분해효소 억제제 등과 병용 투여하여 부작용이 감소하고 치료 효과는 향상하는 파킨슨 질환 개선, 예방 또는 치료용 조성물에 관한 것으로서, 본 발명에 따른 조성물은 신경세포에 대해 신경보호 효능을 가질 뿐만 아니라 파킨슨 질환 동물 모델에 대해 운동능력 및 도파민 전구체 생산에 관여하는 티로신 수산화효소 발현을 향상시키는데 우수한 효과를 나타내므로, 파킨슨 질환의 예방 또는 치료에 유용하게 이용될 수 있다.
Nº publicación: WO2026114055A1 04/06/2026
Applicant:
THE FIRST AFFILIATED HOSPITAL ZHEJIANG UNIV SCHOOL OF MEDICINE ZHEJIANG PROVINCIAL FIRST HOSPITAL [CN]
\u6D59\u6C5F\u5927\u5B66\u533B\u5B66\u9662\u9644\u5C5E\u7B2C\u4E00\u533B\u9662\uFF08\u6D59\u6C5F\u7701\u7B2C\u4E00\u533B\u9662\uFF09
Absstract of: WO2026114055A1
Provided are a hydroxymethyltransferase and a use of a cofactor or metabolic substrate thereof in preparation of drugs for treating neurodegenerative diseases. Specifically, a hydroxymethyl transfer reaction is performed on glycine residues in protein aggregates such as Poly-GA, Poly-GR, and TDP-43 by means of serine hydroxymethyltransferase 1 (SHMT1) and serine hydroxymethyltransferase 2 (SHMT2), so that the aggregates are degraded, thereby reducing pathological aggregation, and thus ameliorating the pathological condition of patients with neurodegenerative diseases such as ALS and FTD and delaying disease progression. A cofactor and a metabolic substrate of the hydroxymethyltransferase can promote the activity of the hydroxymethyltransferase, thereby enhancing the hydroxymethyl transfer effect on the aggregates such as Poly-GA, Poly-GR and TDP-43, and thus can also be used for treatment of the neurodegenerative diseases such as ALS and FTD.
BOPI
Electronic site
